Study suggests experimental drug dismantles 2 key proteins that help tumors survive, adapt
Scientists from Roswell Park Comprehensive Cancer Center report that the investigational anticancer agent FL118 functions as a dual molecular glue degrader that directly targets and degrades the proteins DDX5 and UbE2T, two emerging therapeutic targets linked to cancer survival m